News

Lysander Funds Shares New Distributions Estimates for ETFs

Lysander Funds Shares New Distributions Estimates for ETFs

Lysander Funds Shares New Distributions Estimates

Lysander Funds Limited recently made an announcement about the anticipated cash distributions for December 2024 for their exchange-traded funds (ETFs). The focus is on three notable ETFs: Lysander-Slater Preferred Share ActivETF, Lysander-Canso Corporate Treasury ActivETF, and Lysander-Canso Floating Rate ActivETF. Each of these funds plays an essential role in the investment landscape, catering to different investment strategies.

Overview of the ETFs

Investors are keenly observing the cash distributions for each ETF because they can significantly impact their investment decisions. The ETFs mentioned, identified by their corresponding TSX symbols—PR for Lysander-Slater Preferred Share ActivETF, LYCT for Lysander-Canso Corporate Treasury ActivETF, and LYFR for Lysander-Canso Floating Rate ActivETF—are part of a diverse portfolio that addresses varying investor needs.

Estimated Cash Distributions

The estimated cash distributions for the ETFs through December 2024 are as follows:

  • Lysander-Slater Preferred Share ActivETF (TSX: PR): $0.0400 per unit, with a record date of December 31, 2024, and payment set for January 10, 2025.
  • Lysander-Canso Corporate Treasury ActivETF (TSX: LYCT): $0.3996 per unit, also with a record date of December 31, 2024, and payment to be made on January 10, 2025.
  • Lysander-Canso Floating Rate ActivETF (TSX: LYFR): $0.0782 per unit, maintaining the same timeline with a record date of December 31, 2024, and payment on January 10, 2025.

What to Know Before Investing

Commissions, trailing commissions, management fees, and various expenses might arise with investments in these mutual funds. Prospective investors are encouraged to read the prospectus thoroughly before diving in. It's crucial to note that investment funds are not guaranteed, and their value can fluctuate frequently. Past performance is not always an indicator of future results.

Brokerage Fees and TSX Trading

When purchasing or selling units of an ETF on the Toronto Stock Exchange (TSX), investors should also recognize that they may incur brokerage fees. This is especially pertinent if they buy or sell at a price that deviates from the current net asset value of the ETF. Thus, diligence and preparation are key for investors navigating these financial waters.

Future Outlook and Developments

Lysander Funds is continually adapting its offerings to meet the demands of the market. As they implement innovative strategies, investors can anticipate changes that could enhance the performance of their ETFs. This proactive approach is vital in maintaining competitive advantages and aligning with investor expectations.

Conclusion

Lysander Funds Limited's new cash distribution estimates bring insightful details to their ETF investors. Keeping track of such updates is essential for making informed investment decisions. Whether an investor is eyeing the Lysander-Slater Preferred Share ActivETF, the Lysander-Canso Corporate Treasury ActivETF, or the Lysander-Canso Floating Rate ActivETF, understanding these distributions’ context will guide better financial planning.

Frequently Asked Questions

What are the key features of the Lysander ActivETFs?

The Lysander ActivETFs are designed to tap into different investment strategies with specific focuses. Each has a unique approach to portfolio management, resonating with diverse investor preferences.

How do cash distributions affect my investment?

Cash distributions can enhance your return on investment by providing income while holding the ETF. They represent a portion of the fund's profits returned to investors.

Why is it essential to read the prospectus before investing?

The prospectus outlines the investment objectives, risks, and expenses associated with the ETF. Understanding this information is critical for making informed investment choices.

What should I watch out for when trading ETFs on the TSX?

Be aware of brokerage fees and volatility; buying and selling at different times can lead to variations compared to the current net asset value.

Where can I learn more about Lysander Funds and their offerings?

All relevant information regarding Lysander Funds, their ETFs, and updates can be found on their official website and through financial news outlets.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 4

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 2

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

Insightful Findings on gMG Treatments by UCB at AANEM 2024

Updated Category News Views 127

UCB Highlights Innovations in Generalized Myasthenia Gravis Treatments at AANEM 2024 UCB, a prominent global biopharmaceutical company, is gearing up to present its latest findings in the management of generalized myasthenia gravis (gMG) at the upcoming American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) meeting. The event, which will also feature...

Continue Reading
Lysander Funds Shares New Distributions Estimates for ETFs

Updated Category News Views 131

Lysander Funds Shares New Distributions Estimates Lysander Funds Limited recently made an announcement about the anticipated cash distributions for December 2024 for their exchange-traded funds (ETFs). The focus is on three notable ETFs: Lysander-Slater Preferred Share ActivETF, Lysander-Canso Corporate Treasury ActivETF, and Lysander-Canso Floating Rate ActivETF. Each of...

Continue Reading
Empowering Girls: Pace Center's Initiatives for Growth

Updated Category News Views 350

Introduction to the Capital Campaign Pace Center for Girls Hillsborough is excited to announce its capital campaign aimed at expanding its capacity and enhancing the support provided to girls in the community. Through dedicated efforts such as education, counseling, and training, this campaign signifies a crucial step towards bettering the future for girls in Hillsborough...

Continue Reading
Bank of America Sees Growth in Loans, Deposits Amid Profit Rise

Updated Category News Views 284

Bank of America Reports Increased Earnings and Efficiency Bank of America Corp (NASDAQ: BAC) has announced strong financial results for the second quarter, showcasing impressive growth in loans, deposits, and overall profitability. The bank reported a net income of $7.1 billion, a slight increase from $6.9 billion the previous year, along with an earnings per share (EPS)...

Continue Reading
Investigating Manitex International: A Closer Look at MNTX

Updated Category News Views 72

Examining Fair Treatment for Manitex International Shareholders Ademi LLP has launched an investigation into Manitex International, Inc. (NASDAQ: MNTX) due to concerns about possible breaches of fiduciary duty related to its recent transaction with Tadano. This investigation raises important questions about whether shareholders are being treated fairly in the financial...

Continue Reading